Reported post-surgery 1-year survival rate for oral canine malignant melanoma (cMM) is around 30%; novel treatments are needed as the role of adjuvant chemotherapy is unclear. This prospective study regards adjuvant electrovaccination with human-CSPG4-encoded plasmid in 23 dogs with resected II/III-staged CSPG4-positive oral cMM compared with 19 dogs with resected only II/III-staged CSPG4-positive oral cMM. Vaccination resulted in 6/12/18/24-month survival rate of respectively 95.6/73.9/47.8/30.4% (MST 684 days, range 78-1694, 8/23 dogs alive) and 6/12/18/24-month DFI rate of respectively 82.6/47.8/26.1/17.4% (DFI 477 days, range 50-1694). Non-vaccinated dogs showed 6/12/18/24-month survival rate of respectively 63.2/26.3/15.8/5.3% (MST 200 days, range 75-1507, 1/19 dogs alive) and 6/12/18/24-month DFI rate of respectively 52.6/26.3/10.5/5.3% (DFI 180 days, range 38-1250). Overall survival and DFI of vaccinated dogs was longer in those <20 Kg. In vaccinated and non-vaccinated dogs local recurrence rate was respectively 34.8% and 42% while lung metastatic rate was respectively 39% and 79%.

Prolongation of survival of dogs with oral malignant melanoma treated by en bloc surgical resection and adjuvant CSPG4-antigen electrovaccination / Piras, Lisa Adele; Riccardo, Federica; Iussich, Selina; Maniscalco, Lorella; Gattino, Francesca; Martano, Marina; Morello, Emanuela Maria; LORDA MAYAYO, Saray; Rolih, Valeria; Garavaglia, F.; DE MARIA, Raffaella; Lardone, Elena; Collivignarelli, F.; Mignacca, D.; Giacobino, D.; Ferrone, S.; Cavallo, Federica; Buracco, Paolo. - In: VETERINARY AND COMPARATIVE ONCOLOGY. - ISSN 1476-5829. - 15:3(2017), pp. 996-1013. [doi: 10.1111/vco.12239]

Prolongation of survival of dogs with oral malignant melanoma treated by en bloc surgical resection and adjuvant CSPG4-antigen electrovaccination

GATTINO, FRANCESCA;MARTANO, Marina;MORELLO, Emanuela Maria;BURACCO, Paolo
2017-01-01

Abstract

Reported post-surgery 1-year survival rate for oral canine malignant melanoma (cMM) is around 30%; novel treatments are needed as the role of adjuvant chemotherapy is unclear. This prospective study regards adjuvant electrovaccination with human-CSPG4-encoded plasmid in 23 dogs with resected II/III-staged CSPG4-positive oral cMM compared with 19 dogs with resected only II/III-staged CSPG4-positive oral cMM. Vaccination resulted in 6/12/18/24-month survival rate of respectively 95.6/73.9/47.8/30.4% (MST 684 days, range 78-1694, 8/23 dogs alive) and 6/12/18/24-month DFI rate of respectively 82.6/47.8/26.1/17.4% (DFI 477 days, range 50-1694). Non-vaccinated dogs showed 6/12/18/24-month survival rate of respectively 63.2/26.3/15.8/5.3% (MST 200 days, range 75-1507, 1/19 dogs alive) and 6/12/18/24-month DFI rate of respectively 52.6/26.3/10.5/5.3% (DFI 180 days, range 38-1250). Overall survival and DFI of vaccinated dogs was longer in those <20 Kg. In vaccinated and non-vaccinated dogs local recurrence rate was respectively 34.8% and 42% while lung metastatic rate was respectively 39% and 79%.
Prolongation of survival of dogs with oral malignant melanoma treated by en bloc surgical resection and adjuvant CSPG4-antigen electrovaccination / Piras, Lisa Adele; Riccardo, Federica; Iussich, Selina; Maniscalco, Lorella; Gattino, Francesca; Martano, Marina; Morello, Emanuela Maria; LORDA MAYAYO, Saray; Rolih, Valeria; Garavaglia, F.; DE MARIA, Raffaella; Lardone, Elena; Collivignarelli, F.; Mignacca, D.; Giacobino, D.; Ferrone, S.; Cavallo, Federica; Buracco, Paolo. - In: VETERINARY AND COMPARATIVE ONCOLOGY. - ISSN 1476-5829. - 15:3(2017), pp. 996-1013. [doi: 10.1111/vco.12239]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11381/2870137
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 25
  • ???jsp.display-item.citation.isi??? 21
social impact